Look Forward – Spring 2024 – Issue 182
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Search
Search results
Breakthrough BBS10 treatment marks major milestone
Catherine L’Estrange, aged 11 from London has become the first individual in the UK to receive an investigative gene therapy treatment for retinal dystrophy associated with the BBS10 gene.
Meet a Researcher: Dr Nikolas Pontikos
Dr Nikolas Pontikos is a Senior Research Fellow at UCL Institute of Ophthalmology, and has been working on inherited retinal conditions for several years.
New nanoparticle gene therapy research provides hope for treating inherited sight loss
Researchers from Ghent University have published a study that has the potential to transform inherited retinal disease (IRD) treatment development.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
Ocugen completes dosing of GARDian3 trial for OCU410ST ahead of schedule
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
A fond farewell and a warm welcome
After more than 10 years of service as Chair of the Board of Trustees, Don Grocott has retired.
Vitamin A supplements provides no vision benefit to RP patients
Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Meet a Researcher: Tomasz Tomkiewicz
Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.